These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [The impact of rabeprazole treatment on the quality of life in patients with reflux esophagitis and non-erosive reflux disease]. Liu XH; Ke MY; Song ZQ; Luo JY; Yuan YZ; Hou XH; Zhu YL; Sun J; Zha H Zhonghua Nei Ke Za Zhi; 2005 Nov; 44(11):818-21. PubMed ID: 16316559 [TBL] [Abstract][Full Text] [Related]
5. Measuring symptom distress and health-related quality of life in clinical trials of gastroesophageal reflux disease treatment: further validation of the Gastroesophageal Reflux Disease Symptom Assessment Scale (GSAS). Damiano A; Handley K; Adler E; Siddique R; Bhattacharyja A Dig Dis Sci; 2002 Jul; 47(7):1530-7. PubMed ID: 12141813 [TBL] [Abstract][Full Text] [Related]
6. Validation of the GSFQ, a self-administered symptom frequency questionnaire for patients with gastroesophageal reflux disease. Paré P; Meyer F; Armstrong D; Pyzyk M; Pericak D; Goeree R Can J Gastroenterol; 2003 May; 17(5):307-12. PubMed ID: 12772004 [TBL] [Abstract][Full Text] [Related]
7. Rabeprazole controls GERD symptoms in a patient for whom treatment with lansoprazole failed: first report of "cluster GERD.". Oh DS; Ohning GV; Pisegna JR Dig Dis Sci; 2005 May; 50(5):853-7. PubMed ID: 15912621 [No Abstract] [Full Text] [Related]
8. On-demand therapy with rabeprazole in nonerosive and erosive gastroesophageal reflux disease in clinical practice: effectiveness, health-related quality of life, and patient satisfaction. Ponce J; Argüello L; Bastida G; Ponce M; Ortiz V; Garrigues V Dig Dis Sci; 2004 Jun; 49(6):931-6. PubMed ID: 15309880 [TBL] [Abstract][Full Text] [Related]
10. Dysphagia associated with gastroesophageal reflux disease is improved by proton pump inhibitor. Oda K; Iwakiri R; Hara M; Watanabe K; Danjo A; Shimoda R; Kikkawa A; Ootani A; Sakata H; Tsunada S; Fujimoto K Dig Dis Sci; 2005 Oct; 50(10):1921-6. PubMed ID: 16187198 [TBL] [Abstract][Full Text] [Related]
11. Reductions in symptom distress reported by patients with moderately severe, nonerosive gastroesophageal reflux disease treated with rabeprazole. Damiano A; Siddique R; Xu X; Johanson J; Sloan S Dig Dis Sci; 2003 Apr; 48(4):657-62. PubMed ID: 12741452 [TBL] [Abstract][Full Text] [Related]
12. Review article: relief of symptoms in gastric acid-related diseases--correlation with acid suppression in rabeprazole treatment. Miner P Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():20-9. PubMed ID: 15496215 [TBL] [Abstract][Full Text] [Related]
13. Review of rabeprazole in the treatment of gastro-oesophageal reflux disease. Thjodleifsson B Expert Opin Pharmacother; 2004 Jan; 5(1):137-49. PubMed ID: 14680443 [TBL] [Abstract][Full Text] [Related]
14. [Pharmacogenomical aspects of gastroesophageal reflux disease]. Isaev VA Vestn Ross Akad Med Nauk; 2005; (6):33-6. PubMed ID: 16022110 [TBL] [Abstract][Full Text] [Related]
15. Patients have treatment preferences: a multicentre, double-blind, crossover study comparing rabeprazole and omeprazole. Johnson M; Guilford S; Libretto SE; Curr Med Res Opin; 2002; 18(5):303-10. PubMed ID: 12240793 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of pantoprazole versus ranitidine in the treatment of patients with symptomatic gastroesophageal reflux disease. van Zyl J; van Rensburg C; Vieweg W; Fischer R Digestion; 2004; 70(1):61-9. PubMed ID: 15297779 [TBL] [Abstract][Full Text] [Related]
17. Rabeprazole-based therapy in the management of symptomatic gastroesophageal reflux disease. Sloan S Am J Gastroenterol; 2003 Mar; 98(3 Suppl):S49-55. PubMed ID: 12644031 [TBL] [Abstract][Full Text] [Related]
18. [A randomized, prospective, comparative, multicenter study of rabeprazole and ranitidine in the treatment of reflux esophagitis]. Jeong HY; Lee BS; Sung JK; Lee TY; Yoon SJ; Kim SJ; Chung IK; Lee SH; Shin JE; Lee DS; Baek JT; Nam SW; Yoon SJ; Kim SH; Lee GS; Lee JM; Kim AN; Oh JI Korean J Gastroenterol; 2006 Jan; 47(1):15-21. PubMed ID: 16434864 [TBL] [Abstract][Full Text] [Related]
19. Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States. Caos A; Breiter J; Perdomo C; Barth J Aliment Pharmacol Ther; 2005 Aug; 22(3):193-202. PubMed ID: 16091056 [TBL] [Abstract][Full Text] [Related]
20. Gastroesophageal reflux disease as an etiology of sleep disturbance in subjects with insomnia and minimal reflux symptoms: a pilot study of prevalence and response to therapy. Shaheen NJ; Madanick RD; Alattar M; Morgan DR; Davis PH; Galanko JA; Spacek MB; Vaughn BV Dig Dis Sci; 2008 Jun; 53(6):1493-9. PubMed ID: 17985241 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]